2004
STAT3 induces anti-hepatitis C viral activity in liver cells
Zhu H, Shang X, Terada N, Liu C. STAT3 induces anti-hepatitis C viral activity in liver cells. Biochemical And Biophysical Research Communications 2004, 324: 518-528. PMID: 15474458, DOI: 10.1016/j.bbrc.2004.09.081.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsBlotting, NorthernBlotting, WesternCarcinoma, HepatocellularCell LineCell Line, TumorCytokinesDNA-Binding ProteinsDose-Response Relationship, DrugEnzyme InhibitorsGenes, DominantHepacivirusHumansInflammationInterferonsInterleukin-6LigandsLiverLiver NeoplasmsLuciferasesPlasmidsProtein Structure, TertiaryReverse Transcriptase Polymerase Chain ReactionRibavirinRNARNA, MessengerSTAT3 Transcription FactorTime FactorsTrans-ActivatorsTransfectionTyrphostinsConceptsAnti-HCV activityInterferon alphaSTAT3 activationHuman hepatoma cellsHepatitis C virus infectionHCV subgenomic RNA replicationMain therapeutic regimenC virus infectionChronic liver diseaseCytokines IL-6Replicon cell linesIntracellular antiviral stateCell linesHepatoma cellsLiver diseaseTherapeutic regimenActivation of STAT3IL-6Virus infectionEstrogen receptorIFN treatmentAntiviral genesAntiviral pathwaysAntiviral activityAntiviral stateSustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C
Abdelmalek M, Firpi R, Soldevila‐Pico C, Reed A, Hemming A, Liu C, Crawford J, Davis G, Nelson D. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transplantation 2004, 10: 199-207. PMID: 14762857, DOI: 10.1002/lt.20074.Peer-Reviewed Original ResearchConceptsHepatitis C virusLiver transplant recipientsTransplant recipientsHepatitis CLiver histologyFibrosis stageHCV RNAViral clearanceViral responseCombination therapyDetectable hepatitis C virusRecurrent chronic hepatitis CRecurrent hepatitis C infectionRecurrent hepatitis C virusDetectable HCV RNASustained viral responseChronic hepatitis CInterferon-based treatmentOrthotopic liver transplantationRecurrent hepatitis CHepatitis C infectionInterferon-based therapyRegression of fibrosisGrade of inflammationBaseline histology
2002
Combination of interferon alfa‐2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C
Firpi R, Abdelmalek M, Soldevila‐Pico C, Reed A, Hemming A, Howard R, van der Werf W, Lauwers G, Liu C, Crawford J, Davis G, Nelson D. Combination of interferon alfa‐2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transplantation 2002, 8: 1000-1006. PMID: 12424712, DOI: 10.1053/jlts.2002.34968.Peer-Reviewed Original ResearchConceptsInterferon alfa-2bLiver transplantationAlfa-2bHistological recurrenceViral eradicationHCV RNAWeek 24Recurrent hepatitis C virus (HCV) infectionHCV RNA 6 monthsHepatitis C virus infectionEnd pointProgressive cholestatic diseaseRecurrent HCV infectionSerum HCV RNAC virus infectionLiver transplant recipientsPrimary end pointRecurrent hepatitis CSecondary end pointsGenotype 1 infectionYears of therapyEnd of treatmentHigh viral loadLiver biopsy resultsRecurrent HCV